Open Clinical Trials
Study of MK8669 With Metastatic Bone or Soft-tissue Sarcoma Patients
Phase: |
Phase II - Phase 2 |
Trial for Patients with: |
bone or soft-tissue sarcoma that has metastasized, and who derive benefit following chemotherapy |
Treatment involved: |
Oral treatment |
Age Requirement: |
13 and older |
Location: |
Tokyo, Japan |
| Description | The study evaluates efficacy of MK 8669 (ridaforolimus) when administered as maintenance therapy to patients with metastatic bone or soft-tissue sarcoma in Japan. |
| General Conditions: | |
| Trial Start Date: | November 2009 |
| Trial End Date: | December 2011(estimated) |
| ClinicalTrials.gov: | NCT01010672: detailed information at ClinicalTrials.gov |
| Full Title: | A Phase II Study of MK8669 When Administered as Maintenance Therapy to Patients With Metastatic Bone or Soft-tissue Sarcomas |
| This page was last updated on: | December 12, 2009 |